PHARMACY

H.D. Smith inks partnership with ESPhA

BY David Salazar

SPRINGFIELD, Ill., and NASHVILLE, Tenn. — Independent wholesaler H.D. Smith has a new partnership with group purchasing organization Enhanced Service Pharmacy Alliance, or ESPhA. The partnership brings ESPhA members access to H.D. Smith’s full product line, which includes 9,000-item generic pharmaceutical formulary, and access to the company’s consultant-style account management strategy.

“Our strategic account executives are armed with information, vendors, programs and solutions to help independent pharmacies find their niche in a community and thrive,” H.D. Smith president and CEO Chris Smith said. “By partnering with like-minded pharmacies who are searching for this kind of consultative relationship, we can develop a true ‘win-win’ for both sides. Because we have been supporting independent pharmacies since our founding in 1954, H. D. Smith was a natural fit for this group of driven, community-focused pharmacists.”

ESPhA said it was founded in an effort to make community pharmacies adaptable to a changing healthcare system. The group purchasing organization said it assists its members in implementing enhanced pharmacy services. In addition to the new H.D. Smith Partnership, ESPhA also partners with MedHere Today Consulting, which it said allows it to offer a support system to its members.

“ESPhA’s unique services create opportunities for pharmacists to see beyond the prescription counter, past the day-to-day struggle with reimbursement and DIR issues, and focus on the future of their pharmacy practice,” ESPhA CEO Alan Wilson said. “It is ESPhA’s mission to not only ready our pharmacy members for performance in a quality-driven health environment, but to identify, and even help develop, new, clinically relevant revenue streams for the pharmacy.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

QuintilesIMS rebrands as IQVIA

BY David Salazar

DANBURY, Conn., and RESEARCH TRIANGLE PARK, N.C. — Analytics company QuintilesIMS has a new name. Effective Nov. 6, the company will do business as IQVIA, with its name ticker symbol on the New York Stock Exchange set to switch to IQV on Nov. 15. The name change comes almost a year and a half after Quintiles merged with IMS Health in a $9 billion deal.

“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward,” IQVIA Chairman and CEO Ari Bousbib said. “Our clients have been instrumental in our becoming IQVIA. IMS Health and Quintiles came together because our clients were asking for better, faster ways to bring innovations to patients and capture the improvements the industry has been pursuing for years.”

IQVIA also announced that its client solutions would be powered by the IQVIA CORE, which it says allows the company to offer customized solutions for its clients using advanced analytics and extensive industry knowledge.

“Since the merger, we’ve worked to integrate our capabilities in advanced analytics, leading technologies and therapeutic expertise into powerful, differentiated offerings,” Bousbib said. “Our vision is to outpace the inevitable progress of change across the life sciences and accelerate our ability to empower healthcare decision makers to meet the future head on.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mylan intros generic Clolar for injection

BY David Salazar

PITTSBURGH — Mylan has introduced its generic of Clolar (clofarabine 1 mg/ml) injection. The drug is indicated to treat patients ages 1 year to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior treatment regimens.

The latest launch adds to Mylan’s oncology portfolio, which it said contains more than 40 products. Mylan’s Clolar generic will be available in single-dose vials.

According to data from IQVIA (formerly QuintilesIMS), the drug had U.S. sales of $53 million for the 12 months ended Sept. 30.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?